StockData
Bio-Rad Laboratories, Inc. logo

Bio-Rad Laboratories, Inc. (BIO) stock

BIONYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO.B
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3060% above fair value
$370.17+11.98 (+3.34%)

Close on Nov 18, 2026Market cap $10.00BP/E 45.3Yield –

Earnings

Bio-Rad Laboratories's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$656.40M
+0.5% on a year earlier
Non-GAAP diluted income per share, Q3 FY2026
$2.65
$2.26 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Bio-Rad Laboratories's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$656.40M+0.5%$17.02$2.65Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours$651.00M-0.1%$13.85$2.62Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026during market hours$592.10M+1.1%––Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026during market hours$693.20M+3.9%$26.65$2.51Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025during market hours$653.00M+0.5%-$12.70$2.26Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025during market hours$651.60M+2.1%$11.67$2.61Release
Q1 FY2025ended Mar 31, 2025May 1, 2025during market hours$585.40M-4.2%$2.29$2.54Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025during market hours$667.50M-2.0%-$25.57$2.90Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024during market hours$649.70M+2.8%$23.34$2.01Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024during market hours$638.50M-6.3%-$76.26$3.11Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$610.80M-9.8%$13.45$2.29Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Bio-Rad Laboratories's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
currency-neutral revenuenon-GAAPFY2026-3% – +0.5%-3% – +0.5%ReaffirmedAug 4, 2026
non-GAAP, currency-neutral revenuenon-GAAPFY2026-3% – +0.5%–NewNov 4, 2026
non-GAAP operating marginnon-GAAPFY202610% – 12%–NewNov 4, 2026
operating marginnon-GAAPFY202610% – 12%10% – 12%ReaffirmedAug 4, 2026

Guidance history

Every forecast Bio-Rad Laboratories put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026non-GAAP operating marginFY202610% – 12%New
Nov 4, 2026non-GAAP, currency-neutral revenueFY2026-3% – +0.5%New
Aug 4, 2026operating marginFY202610% – 12%Reaffirmed
Aug 4, 2026currency-neutral revenueFY2026-3% – +0.5%Reaffirmed
Apr 30, 2026operating marginFY202610% – 12%Lowered
Apr 30, 2026currency-neutral revenueFY2026-3% – +0.5%Lowered
Feb 12, 2026estimated non-GAAP operating marginFY202612% – 12.5%New
Feb 12, 2026non-GAAP, currency neutral revenue growthFY2026+0.5% – +1.5%New
Oct 29, 2025non-GAAP operating marginFY202512% – 13%New
Oct 29, 2025non-GAAP, currency-neutral revenue growthFY20250% – +1%New
Jul 31, 2025Non-GAAP operating marginFY202512% – 13%Raised
Jul 31, 2025non-GAAP, currency-neutral revenue growthFY20250% – +1%Narrowed
May 1, 2025operating marginFY202510% – 12%Lowered
May 1, 2025currency-neutral revenueFY2025-1% – +1.5%Lowered
Feb 13, 2025estimated non-GAAP operating marginFY202513% – 13.5%New
Feb 13, 2025non-GAAP, currency-neutral revenue growthFY2025+1.5% – +3.5%Lowered
Oct 30, 2024operating marginFY202412.75% – 13.25%Raised
Oct 30, 2024revenueFY2024-4% – -2.5%Reaffirmed
Aug 1, 2024non-GAAP operating marginFY202412% – 13%Lowered
Aug 1, 2024non-GAAP revenueFY2024-4% – -2.5%Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Bio-Rad Laboratories filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Update
  12. Update
  13. Results
  14. Results
  15. News

See a number that looks wrong?